The Division of Cardiac Surgery, Department of Surgery, University of Western Ontario, London Health Sciences Centre, Lawson Health Research Institute, London, Ont., Canada.
Can J Surg. 2013 Feb;56(1):21-6. doi: 10.1503/cjs.012511.
Cardiac retransplantation remains the most viable option for patients with allograft heart failure; however, careful patient selection is paramount considering limited allograft resources. We analyzed clinical outcomes following retransplantation in an academic, tertiary care institution.
Between 1981 and 2011, 593 heart transplantations, including 22 retransplantations were performed at our institution. We analyzed the preoperative demographic characteristics, cause of allograft loss, short- and long-term surgical outcomes and cause of death among patients who had cardiac retransplantations.
Twenty-two patients underwent retransplantation: 10 for graft vascular disease, 7 for acute rejection and 5 for primary graft failure. Mean age at retransplantation was 43 (standard deviation [SD] 15) years; 6 patients were women. Thirteen patients were critically ill preoperatively, requiring inotropes and/or mechanical support. The median interval between primary and retransplantation was 2.2 (range 0-16) years. Thirty-day mortality was 31.8%, and conditional (> 30 d) 1-, 5- and 10-year survival after retransplantation were 93%, 79% and 59%, respectively. A diagnosis of allograft vasculopathy (p = 0.008) and an interval between primary and retransplantation greater than 1 year (p = 0.016) had a significantly favourable impact on 30-day mortality. The median and mean survival after retransplantation were 3.3 and 5 (SD 6, range 0-18) years, respectively; graft vascular disease and multiorgan failure were the most common causes of death.
Long-term outcomes for primary and retransplantation are similar if patients survive the 30-day postoperative period. Retransplantation within 1 year of the primary transplantation resulted in a high perioperative mortality and thus may be a contraindication to retransplantation.
心脏再次移植仍然是同种异体心脏衰竭患者的最可行选择;然而,考虑到有限的同种异体资源,仔细选择患者至关重要。我们在学术性的三级保健机构分析了再次移植后的临床结果。
在 1981 年至 2011 年间,我们机构进行了 593 例心脏移植手术,其中包括 22 例再次移植。我们分析了接受心脏再次移植的患者的术前人口统计学特征、同种异体移植物丧失的原因、短期和长期手术结果以及死亡原因。
22 例患者接受了再次移植:10 例因移植物血管疾病,7 例因急性排斥反应,5 例因原发性移植物衰竭。再次移植时的平均年龄为 43(标准差 15)岁;6 例为女性。13 例患者术前病情危急,需要使用正性肌力药和/或机械支持。初次移植和再次移植之间的中位数间隔为 2.2(范围 0-16)年。30 天死亡率为 31.8%,再次移植后 30 天以上、1 年、5 年和 10 年的条件生存率分别为 93%、79%和 59%。同种异体血管病(p=0.008)和初次移植和再次移植之间的间隔大于 1 年(p=0.016)对 30 天死亡率有显著有利影响。再次移植后的中位和平均生存时间分别为 3.3 年和 5 年(标准差 6 年,范围 0-18 年);移植物血管疾病和多器官衰竭是最常见的死亡原因。
如果患者在术后 30 天存活,初次移植和再次移植的长期结果相似。初次移植后 1 年内再次移植导致围手术期死亡率较高,因此可能是再次移植的禁忌症。